KIRhub 2.0
Sign inResearch Use Only

GSK3B(GSK3b)

Sign in to save this workspace

UniProt P49841 · PDB · AlphaFold · Substrate: Phospho-Glycogen Synthase peptide · Clone: full-lengthhigh-confidence target

Top inhibitors

#DrugInhibitionResidualKISSGini
1Abemaciclib96.5%3.5%91.480.563
2Defactinib96.3%3.7%92.680.450
3Encorafenib91.5%8.5%98.500.755
4Midostaurin78.4%21.6%78.640.500
5Deucravacitinib75.0%25.0%98.990.718
6Pacritinib70.7%29.3%88.640.452
7Vemurafenib59.9%40.1%96.490.598
8Neratinib56.5%43.5%93.180.597
9Pralsetinib49.2%50.8%93.430.643
10Nintedanib45.9%54.1%90.230.608
11Darovasertib36.8%63.2%96.990.719
12Fostamatinib23.7%76.3%96.740.613
13Dabrafenib23.2%76.8%94.740.633
14Selpercatinib22.6%77.4%96.720.635
15Baricitinib18.9%81.1%97.990.616
16Tepotinib18.7%81.3%99.750.727
17Pirtobrutinib16.3%83.7%99.490.656
18Canertinib16.1%83.9%96.490.671
19Regorafenib16.0%84.0%95.990.719
20Capmatinib15.1%84.9%99.750.582

Paralog block

GSK3A, GSK3B

GSK3AGSK3B

EMT expression

  • Mesenchymal log2(TPM+1): 5.09
  • Epithelial log2(TPM+1): 4.81
  • Fold change: 0.28
  • Status: No significant change

High-confidence drugs

  1. Encorafenib — inh 91.5% · KISS 50.48
  2. Abemaciclib — inh 96.5% · KISS 33.59
  3. Deucravacitinib — inh 75.0% · KISS 31.75

Selectivity landscape vs inhibition on GSK3B

Each point is one of the 92 approved drugs; color = inhibition % on GSK3B.

Mutation lollipop

Cancer-associated mutations plotted by residue position. Marker size + color scale with the number of distinct cancer reports.

Variants (1)

Mutation × cancer associations

MutationCancerOrganSource
C199Acarcinoma_breastBreastref
C199Acarcinoma_pancreasPancreasref

3D structure

Embedded NGL viewer pulls a representative PDB entry (or AlphaFold model if no experimental structure is registered). Heavy bundle — loaded only on demand.

Annotations

Sign in to read and post annotations.

Loading…